Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.49 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.49 |
| ▸ | CCR2 | P41597 | 7/20 | 0.48 |
| ▸ | CCR1 | P32246 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CCR4 | P51679 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3052650 | 0.92 | CCR2 (0.48) | PTGDR2PTGDRCCR2CCR1 | |
| SCHEMBL3050630 | 0.91 | PTGDR2 (0.44) | PTGDR2PTGDRCCR2CCR1CYP3A4 | |
| SCHEMBL3147721 | 0.91 | NAMPT (0.49) | PTGDR2PTGDRCCR2CCR1CYP3A4 | |
| SCHEMBL3050361 | 0.88 | CCR2 (0.55) | PTGDR2PTGDRCCR2CCR1CYP1A2 | |
| SCHEMBL3153386 | 0.87 | CCR2 (0.52) | PTGDR2PTGDRCCR2CCR1CYP1A2 | |
| Hydrochloric Acid SCHEMBL3153990 | 0.86 | CCR2 (0.51) | PTGDR2PTGDRCCR2CCR1CYP1A2 | |
| SCHEMBL3040695 | 0.84 | CCR2 (0.46) | PTGDR2PTGDRCCR2CCR1CYP1A2 | |
| SCHEMBL3045528 | 0.84 | TDP1 (0.54) | PTGDR2 | |
| SCHEMBL3040653 | 0.84 | GPR27 (0.51) | CYP1A2 | |
| SCHEMBL3137630 | 0.84 | CCR2 (0.56) | PTGDR2PTGDRCCR2CCR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2076491-B1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-07-17 | — | — | EP | disclosed |
| US-8481527-B2 | Benzamide derivatives as bradykinin antagonists | RICHTER GEDEON NYRT. (HU) | 2013-07-09 | — | — | US | disclosed |
| EP-2057116-B1 | NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-02-13 | — | — | EP | disclosed |
| US-20130029991-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BEKE GYULA (HU) | 2013-01-31 | — | — | US | disclosed |
| US-20120295910-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BEKE GYULA (HU) | 2012-11-22 | — | — | US | disclosed |
| US-20100105686-A1 | PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-04-29 | — | — | US | disclosed |
| US-20100087423-A1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-04-08 | — | — | US | disclosed |
| EP-2076491-A1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | Richter Gedeon NYRT (HU) | 2009-07-08 | — | — | EP | disclosed |
| EP-2057116-A1 | NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | Richter Gedeon NYRT (HU) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008068540-A1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008050167-A1 | NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295910-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BDKRB1, BDKRB2, HRH4 | PTGDR2 225/4885PTGDR 103/4885CCR2 390/4885 |
| US-20130029991-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BDKRB1, BDKRB2, HRH4 | PTGDR2 233/4885PTGDR 112/4885CCR2 371/4885 |
| US-20100105686-A1 | PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, HRH1 | PTGDR2 244/4885PTGDR 112/4885CCR2 359/4885 |
| US-20100087423-A1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, HRH1 | PTGDR2 195/4885PTGDR 117/4885CCR2 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.